vs
Side-by-side financial comparison of AleAnna, Inc. (ANNA) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
AleAnna, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.5M, roughly 1.4× Prelude Therapeutics Inc). AleAnna, Inc. runs the higher net margin — 2.8% vs -303.5%, a 306.3% gap on every dollar of revenue.
Anna University is a public state university located in Chennai, Tamil Nadu, India. The main campus is in Guindy. It was originally established on 4 September 1978 and is named after C. N. Annadurai, former Chief Minister of Tamil Nadu.
ANNA vs PRLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $6.5M |
| Net Profit | $258.1K | $-19.7M |
| Gross Margin | — | — |
| Operating Margin | 2.4% | -314.1% |
| Net Margin | 2.8% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | 102.7% | 38.9% |
| EPS (diluted) | $0.00 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | — | ||
| Q3 25 | $11.2M | $6.5M | ||
| Q2 25 | $4.0M | — | ||
| Q3 24 | — | $3.0M |
| Q4 25 | $258.1K | — | ||
| Q3 25 | $5.3M | $-19.7M | ||
| Q2 25 | $644.7K | — | ||
| Q3 24 | — | $-32.3M |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 51.0% | -314.1% | ||
| Q2 25 | 14.5% | — | ||
| Q3 24 | — | -1145.9% |
| Q4 25 | 2.8% | — | ||
| Q3 25 | 47.4% | -303.5% | ||
| Q2 25 | 16.0% | — | ||
| Q3 24 | — | -1075.7% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | $0.08 | $-0.26 | ||
| Q2 25 | $0.01 | — | ||
| Q3 24 | — | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.8M | $55.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.7M | $58.5M |
| Total Assets | $101.3M | $94.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | — | ||
| Q3 25 | $31.2M | $55.0M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $153.6M |
| Q4 25 | $58.7M | — | ||
| Q3 25 | $58.3M | $58.5M | ||
| Q2 25 | $52.3M | — | ||
| Q3 24 | — | $156.4M |
| Q4 25 | $101.3M | — | ||
| Q3 25 | $100.1M | $94.8M | ||
| Q2 25 | $89.9M | — | ||
| Q3 24 | — | $197.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $-19.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 14.51× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | — | ||
| Q3 25 | $9.0M | $-19.1M | ||
| Q2 25 | $-700.0K | — | ||
| Q3 24 | — | $-27.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $-27.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | -912.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 2.1% |
| Q4 25 | 14.51× | — | ||
| Q3 25 | 1.69× | — | ||
| Q2 25 | -1.09× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
